Abstract
The impact of programmed death receptor-ligand1 (PD-L1) on costs and value of the immune check point inhibitors (ICPI) has received minimal attention. 1- Design a sliding scale to grade survival in 2nd-line non-small-cell lung cancer (NSCLC). 2- Compare costs and value of Nivolumab (Nivo), Atezolizumab (Atezo) and Pembrolizumab (Pembro) vs. Docetaxel (Doc). Previously reported median overall survival (OS) and prices posted by parent company were utilized. The OS gains over controls in days were graded (gr) from A+ to D. Docetaxel costs were calculated for 6-12 cycles and the ICPI for 1 year. Adverse events treatment costs (AEsTC) were reported separately. The cost/life-year gain (C/LYG) was computed as drug yearly-cost/OS gain over control in days × 360 days. The relative value of the ICPI were expressed as $100,000/C/LYG. Costs of Doc 6 cycles were $23,868, OS/gr 87/C, AEs gr ¾ > 20%, AEsTC $1978 and 6- 12 cycle C/LYG $98,764 -$197,528. Nivo, Atezo and Pembro gr ¾ were < 20% at average costs of $1480. In non-squamous NSCLC, Nivo demonstrated OS/g 84/C and C/LYG $558,326 as compared with 264/A and $177,645 in PD-L1 > 10%. Atezolizumab OS/g were 87/B and C/LYG $551,407 improving in enriched PD-L1 to 162/A and $332,020 respective...Continue Reading
References
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Feb 3, 2011·JAMA : the Journal of the American Medical Association·Vishal RanpuraShenhong Wu
Jun 17, 2014·Lancet·Edward B GaronMaurice Pérol
Feb 19, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B Saltz
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jun 24, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lowell E Schnipper American Society of Clinical Oncology
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Dec 17, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B Saltz
Dec 30, 2015·Lancet·Roy S HerbstEdward B Garon
Jan 14, 2016·Journal of Oncology Practice·Nora B Henrikson, Veena Shankaran
Feb 11, 2016·The Journal of Community and Supportive Oncology·Helmy M Guirgis
Mar 14, 2016·Lancet·Louis FehrenbacherUNKNOWN POPLAR Study Group
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naiyer A RizviScott Antonia
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott GettingerMatthew D Hellmann
Aug 18, 2016·Journal for Immunotherapy of Cancer·Claud Grigg, Naiyer A Rizvi
Sep 9, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N I ChernyM J Piccart
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Oct 18, 2016·The Lancet Oncology·Corey J LangerUNKNOWN KEYNOTE-021 investigators
Nov 8, 2016·The Lancet Oncology·Roy S Herbst, Mario Sznol
Dec 17, 2016·Lancet·Achim RittmeyerUNKNOWN OAK Study Group
Aug 31, 2017·The New England Journal of Medicine·Martin Reck, Klaus F Rabe
Oct 27, 2017·ESMO Open·Urania DafniNathan I Cherny
Nov 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N I ChernyM J Piccart
Citations
Nov 1, 2018·Oncoimmunology·Jeremiah L OyerAlicja J Copik
Oct 5, 2019·Clinical Drug Investigation·Daniel GallacherXavier Armoiry
Jun 22, 2019·Molecular Cancer·Lifeng LiYi Zhang
Nov 17, 2019·Journal of Clinical Medicine·Minchan Gil, Kyung Eun Kim
Jul 11, 2019·Molecular and Clinical Oncology·Rocco GiannicolaPierpaolo Correale
Nov 30, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Katherine SaundersJason J Bergsbaken
Sep 5, 2020·BMC Cancer·Hae-Young ParkJin-Won Kwon
Sep 19, 2019·Nanoscale·Yongjiang LiSunil Krishnan
Oct 9, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yi-He LiuPeng Zhang
Jan 1, 2021·International Journal of Radiation Oncology, Biology, Physics·Elisabeth SchültkeGuido Hildebrandt